The deal represents a more than 60 percent premium to Tesaro's closing price on Friday of $46.38 per share. » Read More
By: Bertha Coombs
This week the Trump administration proposed allowing Medicare Part D pharmacy drug plans to be more selective on branded drugs from what are known as the six special therapeutic classes, which include cancer treatments and H-I-V antiviral drugs. » Read More
The Centers for Medicare and Medicaid Services proposed changes to Medicare prescription drug coverage that would allow insurers to stop covering certain "protected" classes of drugs used to treat common ailments like depression, cancer and HIV. » Read More
By: Vas Narasimhan, CEO of Novartis
Novartis CEO Vas Narasimhan says there is a fundamental challenge with pricing new cell and gene therapies that are potentially curative: how to pay for these therapies and make them available to patients in need. » Read More
If you can't charge "hundreds of thousands" of dollars a year for drugs, will there be drugs for orphan diseases?
Merck reported better-than-expected profit in the first quarter, driven by higher sales of its diabetes drug Januvia and heart drug Zetia.
Obamacare is under threat from politicians. Here's how the affordable care act can work for employers, says industry veteran Denny Weinberg.
Pfizer has approached U.S. cancer drug maker Medivation to express interest in an acquisition, raising the possibility of a bid.
CNBC's Meg Tirrell reports prosecutors may file new charges against Martin Shkreli. His next court hearing is set for June 6th.
Martin Shkreli made an appearance at the U.S. Federal Court in Brooklyn for a hearing related to securities fraud charges.
Pfizer reported a 19.7 percent rise in quarterly revenue, boosted by sales of its new treatments for cancer and its Hospira acquisition.
GlaxoSmithKline CEO Andrew Whitty thinks his company's success has been a product of being patient and investing in innovation.
Sarepta Therapeutics shares soared Monday after the stock was upgraded to "outperform" at Oppenheimer.
Berkshire Hathaway Vice-Chairman Charlie Munger had some harsh words to say about Valeant Pharmaceuticals.
Biotech stocks dragged on the market Friday, and some "Fast Money" traders contended the pain may not be done.
CNBC's Meg Tirrell speaks with Jim Greenwood, Biotechnology Industry Organization President and CEO, and CNBC Contributor and Former Pennsylvania Governor Ed Rendell, about the battle over drug pricing and whether more government regulation is warranted.
Gilead Sciences fell nearly 8 percent, dragging down the S&P 500’s health care sector.
Valeant Pharmaceuticals issued its delayed annual report on Friday, which will help it stave off a default on its $30 billion debt.
Quest Diagnostics said it has received emergency authorization from U.S. regulators to sell the first commercially developed diagnostic test for Zika.
Jesper Brandgaard, CFO of Novo Nordisk, discusses the pharmaceutical company's earnings results and the impact of the declining dollar.
Underlying earnings hit by drug patent expiries.
French drugmaker confident of winning the support of Medivation shareholders for a possible takeover of the U.S. cancer drug company.
Pharmaceuticals need scale in order to negotiate with their healthcare sector counterparts, says H.C. Wainwright's Raghuram Selvaraju
Analysts expected Gilead to report earnings of about $3.15 a share on $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.